OraQuick(R) In-Home HIV Test Named a "Best Invention of 2012" by TIME Magazine
06 11월 2012 - 2:00AM
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the
company's OraQuick® In-Home HIV Test, the first ever in-home rapid
infectious disease test made available directly to consumers, has
been named one of the "Best Inventions of 2012" by TIME. The
OraQuick® In-Home HIV Test is the only health innovation included
on this prestigious list for 2012.
"With just a swab of saliva and 20 minutes, OraQuick® can
identify the antibodies that signal HIV infection," TIME reported
in its annual story on the most important inventions of the year.
This is the second such recognition for OraSure from TIME, as the
OraQuick® ADVANCE HIV 1/2 Antibody professional test was honored in
2004. At that time, the U.S. Food and Drug Administration (FDA)
approved the first oral fluid rapid HIV test for health care
professionals and this year, the same proven technology was made
available for consumers to use at home.
"The OraQuick® In-Home HIV Test is a breakthrough product in the
fight against HIV and AIDS because it empowers more people to learn
their HIV status in the comfort and privacy of their own homes,"
said Douglas A. Michels, President and Chief Executive Officer of
OraSure Technologies. "OraSure is extremely proud to be recognized
by TIME for this innovation."
The OraQuick® In-Home HIV Test, approved by the U.S. Food and
Drug Administration (FDA) in July 2012, detects antibodies to both
HIV-1 and HIV-2 with an oral swab, providing a confidential in-home
testing option with results in as little as 20 minutes. The in-home
test, which is now available at major retailers nationwide, is an
over-the-counter version of OraQuick ADVANCE®, an oral swab rapid
test with more than 25 million units sold in the professional
market, including doctors, hospitals, clinics and other trained
professionals. The OraQuick In-Home HIV Test is available at
thousands of retailers nationwide and online at OraQuick.com.
To ensure optimal support for individuals using the OraQuick®
In-Home HIV Test, OraSure offers live support and comprehensive
referral services 24 hours a day, seven days a week, every day of
the year, through a toll-free support center and comprehensive
consumer website. The OraQuick® Support Center is staffed with
highly trained, bi-lingual (English/Spanish) representatives who
are available by telephone at 866-436-6527 to answer questions
about HIV/AIDS and using and interpreting the test. They also
provide referrals to follow-up and care, and can take orders for
the OraQuick In-Home HIV Test. Additionally, the product website
provides access to resources and referral to follow-up counseling,
confirmatory testing and medical care.
Visit OraQuick.com for more information.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of oral fluid diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions for detecting various drugs of abuse. In July
2012, the Company received approval from the U.S. Food and Drug
Administration for the Company's OraQuick® In-Home HIV Test for
sale directly to consumers in the over-the-counter (OTC) market –
making it the first and only rapid OTC HIV test approved in the
U.S. In addition, the Company is a leading provider of oral fluid
sample collection, stabilization and preparation products for
molecular diagnostic applications. OraSure's portfolio of products
is sold globally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their
health.
For more information on OraSure Technologies, please visit
www.orasure.com.
The OraSure Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6440
Important Information Regarding the OraQuick In-Home HIV Test -
You must be 17 or older to use this test. A positive result
with this test does not mean that you are definitely infected with
HIV, but rather that additional testing should be done in a medical
setting. A negative result with this test does not mean that you
are definitely not infected with HIV, particularly when exposure
may have been with in the previous three months. If your test is
negative and you engage in activities that put you at risk for HIV
on a regular basis, you should test regularly. This product should
not be used to make decisions on behavior that may put you at
increased risk for HIV.
CONTACT: Investor Contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
investorinfo@orasure.com
Media Contact:
Ashley Buford
GolinHarris for OraSure Technologies
917-653-5694
abuford@golinharris.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024